Highlights

  • Archer Materials shares rose 7.14% to AUD 0.30 on 29 April 2026 as investors reacted positively to its Q3 FY26 update.
  • Progress made toward qubit development, including readout and control improvements.
  • Biochip Alpha-prototype achieved clinically relevant potassium measurement accuracy of ±0.3 mM.
  • First phase of Quantum Machine Learning (QML) Fraud detection project completed.
  • Cash position stood at AUD 10.3 million with no Debt at quarter end.
  • Work underway to scale carbon material production for wafer-level device fabrication.

Archer Materials Limited (ASX:AXE) shares climbed 7.14% to AUD 0.30 during the afternoon session on 29 April 2026, following the release of its Q3 FY26 Activities Report and Appendix 4C for the quarter ended 31 March 2026. The stock remains 11.11% higher over the past year, with the latest update indicating continued progress across its Quantum Computing, sensing, and medical diagnostics programs.

The market reaction appears aligned with the company’s reported advancement in multiple technical milestones, alongside steady progress toward commercialisation pathways and a maintained cash position with no Debt.

Company Overview and Technology Focus

Archer Materials operates within the semiconductor and quantum technology space, developing advanced chip-based solutions across computing, sensing, and medical diagnostics. Its core focus lies in building enabling technologies such as qubits for Quantum Computing systems, alongside biosensing platforms and quantum-enhanced software applications.

The company leverages collaborations with research institutions and industry partners to advance its technologies toward real-world deployment across sectors including healthcare, finance, and advanced computing.

Qubit Development and Quantum Progress

During Q3 FY26, Archer continued advancing its 12CQ Project, which is centred on the development of a qubit device. The company reported ongoing work on improving qubit readout and control capabilities—key elements required for functional Quantum Computing systems.

The development process involves constructing nanoscale transistors using Archer’s carbon-based materials, including graphene and nano-onions. These devices are designed to isolate and analyse single electrons, allowing the determination of spin states through magnetic field interactions. This process forms the basis of qubit functionality.

Testing and measurement activities continued throughout the quarter, contributing to iterative improvements in device design and fabrication. The company also noted that in-house measurement capabilities have reduced turnaround times, supporting faster development cycles.

In parallel, Archer is working to scale up carbon material growth and device fabrication to wafer scale, which is considered a step toward enabling larger-scale production and integration into broader quantum systems.

The company also reported ongoing engagement with quantum technology partners and continued commercial discussions, alongside technical development milestones.

Emergence Quantum Collaboration

Archer progressed its collaboration with Emergence Quantum during the quarter, focusing on the application of graphene-based technologies. The Partnership is currently in its initial phase, involving mapping graphene applications across multiple quantum domains and establishing development pathways.

The next stage of the collaboration is expected to involve prototype demonstrations targeting high-impact use cases, forming part of Archer’s broader strategy to accelerate qubit development and application.

Advancements in Quantum Sensing

In the sensing segment, Archer continued its collaboration with the Swiss Federal Technology Institute of Lausanne (EPFL). Activities during the quarter included carbon film growth and the fabrication of test devices, which were subsequently characterised and measured.

The company reported progress in collecting electrical detection of magnetic resonance (EDMR) results. The objective is to achieve EDMR signatures at room temperature, which would support the development of quantum sensing devices such as magnetometers.

These devices could have potential applications in areas including medical diagnostics, imaging, and navigation, depending on further development outcomes.

Quantum Machine Learning (QML) Milestones

Archer completed the first phase of its Quantum Machine Learning project during the quarter. The initiative is focused on applying Quantum Computing techniques to enhance Fraud detection in financial transactions.

The initial phase involved selecting and preparing a dataset of over 280,000 bank transaction records, including known fraudulent cases. Data reduction techniques were applied to align with current quantum hardware limitations, while maintaining key features necessary for model Training.

This dataset has been widely used in classical Machine Learning, allowing for benchmarking between traditional and quantum-based approaches.

The project has now moved into its next stage, which includes simulation and benchmarking of QML models. Archer indicated that a full QML prototype is targeted for completion by the end of 2026.

Biochip Development and Clinical Progress

A key development during the quarter was the creation of an Alpha-prototype of Archer’s Biochip, designed to measure potassium levels in blood. The device is intended for monitoring conditions associated with potassium imbalances, including kidney disease, cardiovascular disease, and diabetes.

The Alpha-prototype demonstrated potassium measurement accuracy within ±0.3 mM, meeting requirements aligned with Clinical Laboratory Improvement Amendments (CLIA) standards for comparable laboratory testing.

The prototype integrates multiple components, including the sensing chip, test cartridge, and readout electronics. The system also demonstrated stable performance across repeated measurements.

Development work included the design of microfluidic systems to handle small volumes of blood, integration of chip packaging with printed circuit boards, and refinement of electronic readout systems.

These components collectively form the foundation for future Manufacturing processes and product development.

Archer is now progressing toward the next phase, which involves developing a Beta-prototype later in 2026. This version is expected to support clinical trial initiation and facilitate discussions with medical device manufacturers and potential licensing partners.

The company also reported expanded efforts in exploring additional sensing applications beyond potassium detection, alongside ongoing Market Analysis for future medical device opportunities.

Financial Position and Cash Flow Overview

Archer reported a cash balance of AUD 10.3 million at the end of the March 2026 quarter, with no outstanding Debt. This position is intended to support ongoing Research and Development activities and commercial initiatives.

From a Cash Flow perspective, the company recorded net cash inflow from Operating Activities of AUD 139,000 for the quarter, while year-to-date operating Cash Flow stood at an outflow of AUD 3.245 million.

Operating expenditures included AUD 680,000 in Research and Development costs, AUD 852,000 in staff costs, and AUD 473,000 in administration and corporate expenses for the quarter.

Government grants and tax incentives contributed AUD 2.102 million year-to-date, supporting the company’s funding structure.

Investing activities included AUD 73,000 allocated toward intellectual property during the quarter, while total cash and cash equivalents at the end of the period stood at AUD 10.336 million.

Payments to related parties, including director fees, amounted to AUD 154,000 during the quarter.

What This Means for Investors?

Archer’s Q3 FY26 update reflects continued advancement across its key technology platforms, including Quantum Computing, sensing, and medical diagnostics. Progress in qubit development, the completion of the initial QML phase, and the Biochip Alpha-prototype milestone collectively indicate movement toward commercialisation pathways.

The company’s Debt-free Balance Sheet and cash position of AUD 10.3 million provide funding support for ongoing development activities. The transition from research-focused milestones to prototype development and potential clinical applications appears to be a central theme in the current phase.

The share price movement on 29 April 2026 suggests that investors are responding to the alignment of technical progress, product development milestones, and financial stability.